Advertisement
YOU ARE HERE: LAT HomeCollectionsSepsis Disease
IN THE NEWS

Sepsis Disease

FEATURED ARTICLES
BUSINESS
November 22, 2001 | BLOOMBERG NEWS
Eli Lilly & Co. won Food and Drug Administration approval of its Xigris drug for severe sepsis, the first treatment approved for the often fatal overreaction to infection. Analysts estimate annual sales for Xigris, a genetically engineered protein, will top $1 billion within a few years of its introduction. Lilly needs new products to make up for declining sales of its Prozac antidepressant, which lost U.S. patent protection in August.
ARTICLES BY DATE
SCIENCE
January 12, 2008 | From Times Staff and Wire Reports
Using steroids or intensive insulin therapy -- standard hospital remedies for life-threatening blood infections called sepsis -- doesn't work and may increase the risk of dangerous side effects, researchers reported Thursday in the New England Journal of Medicine. About 750,000 Americans develop sepsis every year, with 215,000 dying, according to the Society of Critical Care Medicine in Chicago. A review of 499 patients found no significant difference in mortality between those given low-dose hydrocortisone for 11 days and those who received placebos.
Advertisement
SCIENCE
January 12, 2008 | From Times Staff and Wire Reports
Using steroids or intensive insulin therapy -- standard hospital remedies for life-threatening blood infections called sepsis -- doesn't work and may increase the risk of dangerous side effects, researchers reported Thursday in the New England Journal of Medicine. About 750,000 Americans develop sepsis every year, with 215,000 dying, according to the Society of Critical Care Medicine in Chicago. A review of 499 patients found no significant difference in mortality between those given low-dose hydrocortisone for 11 days and those who received placebos.
BUSINESS
August 27, 2002 | Bloomberg News
Eli Lilly & Co. said it won European Union approval for Xigris, the first drug designed for a sometimes fatal overreaction to infection known as sepsis. Lilly won U.S. approval of Xigris last year. First-half Xigris sales were $44.6 million. In April, the Indianapolis-based company cut its 2002 and 2003 profit forecasts, in part because of disappointing sales of Xigris. Lilly wouldn't reveal its European sales estimates for Xigris, a company spokeswoman said. Lilly shares rose 8 cents to $59.
NEWS
February 10, 2001 | THOMAS H. MAUGH II, TIMES MEDICAL WRITER
A new drug to fight bacterial infections in the bloodstream could save 50,000 lives per year in the United States, researchers said Friday. Pharmaceutical companies have been investing huge amounts of time and money to find a drug to combat sepsis, which afflicts 750,000 Americans each year and kills as many as 250,000, but the new drug is the first to show any benefit. "This is truly a landmark trial," Dr.
BUSINESS
July 19, 1994 | From Reuters
Synergen Inc. said Monday that its lead product, Antril, has failed in clinical trials for treatment of the blood infection sepsis and that it will cut its staff in half, an announcement that sparked a steep drop in the company's stock price. Synergen's stock lost nearly half its value in heavy trading after the announcement and closed down $4.375 at $4.50 on the Nasdaq, where it was the second-most-active issue in afternoon trading.
BUSINESS
August 27, 2002 | Bloomberg News
Eli Lilly & Co. said it won European Union approval for Xigris, the first drug designed for a sometimes fatal overreaction to infection known as sepsis. Lilly won U.S. approval of Xigris last year. First-half Xigris sales were $44.6 million. In April, the Indianapolis-based company cut its 2002 and 2003 profit forecasts, in part because of disappointing sales of Xigris. Lilly wouldn't reveal its European sales estimates for Xigris, a company spokeswoman said. Lilly shares rose 8 cents to $59.
BUSINESS
November 22, 2001 | BLOOMBERG NEWS
Eli Lilly & Co. won Food and Drug Administration approval of its Xigris drug for severe sepsis, the first treatment approved for the often fatal overreaction to infection. Analysts estimate annual sales for Xigris, a genetically engineered protein, will top $1 billion within a few years of its introduction. Lilly needs new products to make up for declining sales of its Prozac antidepressant, which lost U.S. patent protection in August.
NEWS
February 10, 2001 | THOMAS H. MAUGH II, TIMES MEDICAL WRITER
A new drug to fight bacterial infections in the bloodstream could save 50,000 lives per year in the United States, researchers said Friday. Pharmaceutical companies have been investing huge amounts of time and money to find a drug to combat sepsis, which afflicts 750,000 Americans each year and kills as many as 250,000, but the new drug is the first to show any benefit. "This is truly a landmark trial," Dr.
BUSINESS
July 19, 1994 | From Reuters
Synergen Inc. said Monday that its lead product, Antril, has failed in clinical trials for treatment of the blood infection sepsis and that it will cut its staff in half, an announcement that sparked a steep drop in the company's stock price. Synergen's stock lost nearly half its value in heavy trading after the announcement and closed down $4.375 at $4.50 on the Nasdaq, where it was the second-most-active issue in afternoon trading.
Los Angeles Times Articles
|